Ara papain biography of alberta
•
Published in final edited form as: Allergy. 2023 Feb 26;78(5):1148–1168. doi: 10.1111/all.15678
Abstract
Tremendous progress in the last few years has been made to explain how seemingly harmless environmental proteins from different origins can induce potent Th2-biased inflammatory responses. Convergent findings have shown the key roles of allergens displaying proteolytic activity in the initiation and progression of the allergic response. Through their propensity to activate IgE-independent inflammatory pathways, certain allergenic proteases are now considered as initiators for sensitization to themselves and to non-protease allergens. The protease allergens degrade junctional proteins of keratinocytes or airway epithelium to facilitate allergen delivery across the epithelial barrier and their subsequent uptake by antigen-presenting cells. Epithelial injuries mediated by these proteases together with their sensing by protease-activated receptors (PARs) elicit potent inflammatory responses resulting in the release of pro-Th2 cytokines (IL-6, IL-25, IL-1β, TSLP) and danger-associated molecular patterns (DAMPs; IL-33, ATP, uric acid). Recently, protease allergens were shown to cleave the protease sensor domain of IL-33 to p
•
EP1366081B1 - Fraktionierung von getreide und daraus resultierende produkte - Dmoz Patents
Info
- Publication number
- EP1366081B1 EP1366081B1EP01971578AEP01971578AEP1366081B1EP 1366081 B1EP1366081 B1EP 1366081B1EP 01971578 AEP01971578 AEP 01971578AEP 01971578 AEP01971578 AEP 01971578AEP 1366081 B1EP1366081 B1EP 1366081B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- flour
- beta
- glucan
- fiber
- organic solvent
- Prior deceit date
- Legal side (The statutory status survey an supposal and attempt not a legal ending. Google has not performed a permissible analysis at an earlier time makes no representation translation to say publicly accuracy be more or less the opinion listed.)
- Expired - Lifetime
•
Abstract
Severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), the pathogen of the Coronavirus disease-19 (COVID-19), is still devastating the world causing significant chaos to the international community and posing a significant threat to global health. Since the first outbreak in late 2019, several lines of intervention have been developed to prevent the spread of this virus. Nowadays, some vaccines have been approved and extensively administered. However, the fact that SARS-CoV-2 rapidly mutates makes the efficacy and safety of this approach constantly under debate. Therefore, antivirals are still needed to combat the infection of SARS-CoV-2. Papain-like protease (PLpro) of SARS-CoV-2 supports viral reproduction and suppresses the innate immune response of the host, which makes PLpro an attractive pharmaceutical target. Inhibition of PLpro could not only prevent viral replication but also restore the antiviral immunity of the host, resulting in the speedy recovery of the patient. In this review, we describe structural and functional features on PLpro of SARS-CoV-2 and the latest development in searching for PLpro inhibitors. Currently available inhibitors targeting PLpro as well as their structural basis are also summarized.
Keywords: COVID-19, SARS-CoV-2, papa